Cullinan Therapeutics, Inc. (NASDAQ: CGEM) Investment Analysis

Font: Financial Modeling Prep  • Feb 26, 2026

• The consensus price target for Cullinan Therapeutics, Inc. (NASDAQ: CGEM) has slightly decreased over the past year but remains stable in recent months.
• Morgan Stanley analysts have set a price target of $19 for CGEM, indicating a positive outlook for the stock.
• Cullinan's focus on developing therapies for cancer and immune-related diseases positions it well in the competitive biopharmaceutical industry.

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company that focuses on developing therapies for cancer and immune-related diseases. Founded in 2016 and based in Cambridge, Massachusetts, Cullinan is advancing a pipeline of promising candidates, including CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company is committed to bringing innovative treatments to the market.

The consensus price target for CGEM stock has shown some fluctuations over different time frames. Last month, the average price target was $30, which slightly increased to $30.25 last quarter. However, over the past year, the average price target was higher at $30.83. This indicates a slight decrease in the consensus price target over the past year, with a more stable outlook in recent months.

In comparison to Precision BioSciences (NASDAQ: DTIL), another small-cap medical company, Cullinan Therapeutics is being evaluated for its investment potential. Analysts at Morgan Stanley have set a price target of $19 for CGEM, suggesting a positive outlook for the company's stock. This target reflects the analysts' confidence in Cullinan's potential to deliver value to investors.

When considering investing in Cullinan Therapeutics, it's important to look at various factors such as company news, clinical trial results, and broader market conditions. The company's focus on oncology and immuno-oncology therapies, along with its promising pipeline, positions it well in the competitive biopharmaceutical industry. Investors should weigh these factors alongside the consensus price target trends to make informed decisions.